Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
Would presence of an SVC stent affect your decision to offer BID vs once-daily chemoradiation for SCLC?
Does presence of an SVC stent preclude 60/40 or other BID dose escalation for SCLC?
Related Questions
What are your top takeaways in Thoracic Cancers from ASTRO 2024?
Is there a concern for using FFF beams in single isocenter multi target lung SBRT?
What is the role of consolidative durvalumab and prophylactic cranial irradiation in patients with stage I small cell lung cancer?
Would you give lung SBRT to a patient with bullous pemphigoid on the chest and torso?
Would you consider omitting concurrent chemoradiation for a patient with stage III EGFR-mutant NSCLC and initiating treatment with osimertinib instead?
Do you recommend consolidation immunotherapy after SBRT or surgery and chemo for T1-T2N0 SCLC?
Would you offer lung SBRT in a patient with Pulmonary Langerhans Cell Histiocytosis (PLCH)?
For NSCLC patients treated with neoadjuvant chemoimmunotherapy and surgery with ypN2 disease, what factors would cause you to recommend PORT?
Would you offer adjuvant radiation therapy for a completely resected, node positive mucoepidermoid carcinoma of the lung?
How does neoadjuvant chemo-immunotherapy impact your decision on hypofractionation/dose fractionation for locally advanced NSCLC, now getting RT alone?